SUMMARY, EXPLANATION AND LIMITATIONS:
The gene product HER-2/neu (also known as c-erbB-2 gene product, p185 or CD380) belongs to the protein family of epidermal growth factor receptors. It is a 185 kDa transmembrane glycoprotein with tyrosine kinase activity. The antibody clone CB11 is directed against the internal domain of the oncoprotein.
Some adenocarcinomas including carcinomas of the gastrointestinal tract and ovarian carcinomas as well as up to 30% of all breast carcinomas are showing an overexpression of HER2. It was shown that overexpression of HER2 is correlated with bad prognosis. Similar observations were made for osteosarcomas as well as stomach and bladder carcinomas. It was shown that overexpression of Her2 is correlated with bad prognosis. Since the HER2 protein was identified as major diagnostic target the immunohistochemical determination of HER2 has gained great importance. It was reported by different research groups that 15-30% of all invasive ductal breast carcinomas as
well as 90% of ductal breast carcinomas in situ (DCIS) stain positive for HER2. Proof of HER2 overexpression in breast carcinoma is regarded to be necessary for a therapy with Trastuzumab (Herceptin™).
Immunogen: Synthetic peptide corresponding to the intracellular domain of human HER2/neu protein.
Staining pattern: Cell membrane.
Positive control: Tissue sample from breast carcinoma.
This antibody is designed for the specific localization of human HER2 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
This antibody is recommended to determine the levels of expression of the oncoprotein c-erbB-2 in adenocarcinomas of breast, lung and other locations and transitional cell carcinomas of the urinary tract. Immunohistochemical staining of this oncoprotein is associated with gene amplification. In the case of breast cancer, overexpression of this oncoprotein has been shown to be associated with a worse prognosis.